CORRECTED: Novartis Knocks Colombia Over Leukemia Drug Price Control

Law360, New York (December 1, 2016, 7:22 PM EST) -- Swiss pharmaceutical giant Novartis has threatened to file an investor-state claim against Colombia over the country's decision to require a price control on Novartis' leukemia drug Glivec, a spokesman for the company confirmed on Thursday. 

The spokesman told Law360 that the company had filed its notice of dispute over certain intellectual property rights under a bilateral investment treaty between the South American nation and Switzerlan in April, several months before Colombia's Ministry of Health issued a decision in June to enforce a declaration of public interest requiring a price control on Glivec. 

The declaration issued by the Colombian health ministry stipulates that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!